# CERTIFICATE OF ANALYSIS

| | |
|---|---|
| **Product Name** | NVG-291, TAT-ISP (Human), Cat.#: 319761 (TFA removed) |
| **Lot No.** | MTFB21218-261009 |
| **Sequence** | GRKKRRQRRRCDMAEHTERLKANDSLKLSQEYESI-NH2 (HCl Salt) |
| **Dissolution condition** | 100%H2O |
| **Modification** | HCl Salt |
| **Molecular Weight (MW)** | 4288.82 |
| **Storage** | -20°C |

| **Test Items** | **Specifications** | **Results** |
|---|---|---|
| **MW by MS** | 4289.25 | Conforms |
| **Purity by HPLC** | >98% | 98.100% |
| **Peptide content** | N/A | 84.23% |
| N content | N/A | 18.48% |
| TFA content | ＜1% | 0.45% |
| Endotoxin content | ＜10 EU/mg | Conforms |
| **Appearance** | White to off-white lyophilized powder | Conforms |
| **Quantity** | 1400.0 mg | 5.0 mg*80 + 100.0 mg*10 |

NovoPro Bioscience Inc. (hereafter NovoPro) warrants material of said quality at the time of sale. It is the sole responsibility of the customers to determine the adequacy of all materials for any intended or specific purpose or use. NovoPro's sole obligation is to replace the material up to the extent of the purchase price. This warranty applies only to products in original packaging and does not apply to a product which has been tampered with or altered in any way in or which has been misused or damaged by accident or negligence. All claims must be received writing (by fax or email) within 30 days from date when product arrive at the destination city and failure to do so shall constitute a waiver by customers for any and all such claims.

Certified by:

Quality Assurance Department

Oct/22/2026


NovoPro Biosciences Inc. VERIFIED Quality Control

## Sample Information

| | |
|---|---|
| Order ID | :MTFB21218 |
| Name | :NVG-291, TAT-ISP (Human), Cat.#: 319761 (TFA removed) |
| Sequence | :GRKKRRQRRRCDMAEHTERLKANDSLKLSQEYESI-NH2(HCl Salt) |
| Lot. No | :MTFB21218-261009 |
| Pump A | :0.1%Trifluoroacetic in 100% water |
| Pump B | :0.1%Trifluoroacetic in 100% acetonitrile |
| Total Flow | :1ml/min |
| Wavelength | :214nm |
| Analytial column type | :Kromasil 100-5-C18 (4.6*250mm*5 μm) |
| Dissolution method | :100%H2O |
| Inj. Volume | : 15ul |

| Time | Module | Action | Value |
|---|---|---|---|
| 0.01 | Pumps | B.Conc | 10 |
| 30.00 | Pumps | B.Conc | 40 |
| 33.00 | Pumps | B.Conc | 100 |
| 38.00 | Pumps | B.Conc | 100 |
| 40.00 | Pumps | B.Conc | 10 |
| 50.00 | Controller | Stop | |

## Chromatogram





## Peak Table

Detector A 214nm

| Peak# | Ret. Time | Area | Height | Area% |
|---|---|---|---|---|
| 1 | 17.287 | 122036 | 10158 | 1.900 |
| 2 | 17.675 | 6301906 | 637909 | 98.100 |
| Total | | 6423943 | 648068 | 100.000 |

MS Spectrum




## Sample Information

| | | | | | |
|---|---|---|---|---|---|
| Dissolution method | :15%ACN+85%H2O | Interface | :ESI | Prerod Bias | :+4.5kv |
| Date Acquired | :2026/10/21 10:17:52 | Nebulizing Gas Flow | :1.50L/min | Detector | :-0.2kv |
| Injection Volume | :0.2ul | CDL Temp | :250℃ | T.Flow | :0.2ml/min |
| Block Temp | :200 | CDL Volt | :0v | B.conc | :50%H2O/50%MEOH |

| | |
|---|---|
| Order ID | :MTFB21218 |
| Name | :NVG-291, TAT-ISP (Human), Cat.#: 319761 (TFA removed) |
| Sequence | :GRKKRRQRRRCDMAEHTERLKANDSLKLSQEYESI-NH2 (HCl Salt) |
| Lot.No | :MTFB21218-261009 |
| Theoretical | :4288.82 |
| Observed | :4289.25 |

# Instructions for dissolving NVG-291, TAT-ISP (Human)

The NVG-291 is soluble in pure water, 1 x PBS, or Bacteriostatic (BAC) water.

The suggested concentration is 5.0 mg/ml.

The steps are as below:

1. Adding 1.0 ml ultrapure water to the 2.0 ml tube of NVG-291;
2. Wait about 1 minute at room temperature until the solution is clear, which indicates the peptide is fully dissolved;
3. Use a sterile 0.22 µm membrane filter for a particle-free and bacteria-free NVG-291 solution.
   For example, Catalog# SLGPR33RB, Millipore Millex-GP Syringe Filter Unit, 0.22 µm, polyethersulfone, 33 mm, gamma sterilized.

Detailed information of NVG-291 can be found at:

https://nervgen.com/wp-content/uploads/2024/02/NGEN-NR-Ph1b-2a-Study-Update-FINAL.pdf

https://nervgen.com/pipeline/sci/

References of NVG-291

1. Kondiles, Bethany R et al. “Lessons Learned and Recommendations from a SCOPE Spinal Cord Injury Neurorestorative Clinical Trials Update.” Neurotrauma reports vol. 6,1 210-231. 5 Mar. 2025. https://doi.org/10.1089/neur.2024.0163

2. Lang, Bradley T et al. “Modulation of the proteoglycan receptor PTPσ promotes recovery after spinal cord injury.” Nature vol. 518,7539 (2015): 404-8. https://doi.org/10.1038/nature13974